February 20, 2026 02:46 pm (IST)

Make this your homepage

All Finance

PM Modi warns ‘AI must not control humans’ as India unveils bold tech vision at AI Impact Summit 2026 | Former South Korean President Yoon Suk Yeol sentenced to life over failed martial law bid | Tata Group joins hands with OpenAI in massive AI push to transform India and global industries | Epstein Files row: Bill Gates to skip keynote address at AI Summit 2026 | AI Impact Summit: Google launches game-changing America-India Connect plan with $15 billion backing | AI takes centre stage as Modi meets Google CEO Sundar Pichai in Delhi | G7 Spotlight: Emmanuel Macron invites Narendra Modi for 2026 Summit | AI Summit embarrassment! Galgotias University asked to vacate stall after ‘own robot’ exposed as China’s Unitree Go2 | Actor Rajpal Yadav granted interim bail in ₹9-crore cheque bounce case | Learn AI or become redundant: Microsoft India President issues stark message

Dr Reddy's acquires rights to an investigational anti-cancer agent

India blooms News Service | | Mar 31, 2016, at 07:47 pm

#Raghav Chari # Executive Vice President # Proprietary Products Group # Dr Reddy

Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.

Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am

In Images: Glimpses from Bengali film Fatafati's premiere May 13, 2023, at 08:39 pm